Insights you can use from the thought leaders behind Oncology Voice Network, delivered to you every week.
Organizations are investing in AI without fixing the underlying data problem. Unstructured, siloed, and inconsistent data will produce unreliable AI.
...
Competitive secrecy prevents organizations from sharing safety signals, efficacy data, and clinical insights that could improve patient outcomes.
...
The industry tracks reach, frequency, and engagement. But none of those metrics tell you whether you actually changed a clinical decision.
...
Social media has shifted oncology influence. The loudest voices shaping patient decisions may have no clinical credentials at all.
...
When organizations outsource everything, they lose the institutional knowledge and strategic control needed to make critical development decisions.
...
Compliance teams are brought in too late to shape strategy and too early to be ignored. The result is friction that slows everything down.
...
When regional teams operate without alignment to the global plan, the result is fragmented execution, duplicated effort, and inconsistent evidence.
...
The industry promotes its best scientists into leadership roles — then gives them no training, no support, and no infrastructure to succeed.
...
When preclinical and clinical teams operate in isolation, critical scientific insights get lost in the handoff — and programs pay the price.
...
When development plans are copied from one program to the next without rethinking the strategy, the industry repeats mistakes at scale.
...
Clinical trials are designed for ideal patients. Real patients live with comorbidities, transportation barriers, and caregiver burdens that protocols never account for.
...
Launch teams build strategies on data they already have — but the data they're missing is what determines whether the launch succeeds.
...
The pressure to launch fast can undermine the evidence base, the market position, and the long-term value of a product.
...
A drug can win regulatory approval and still never reach the patients who need it. Approval is not the finish line — access is.
...
The industry generates more data than ever. The problem is that most of it never reaches the people making the decisions that matter.
...
A patient with stage-four lung cancer drives three hours to a clinical trial site.
The visit is for a five-minute blood draw.
He drops out the same day.
It was logged as a...
Clinical trial design fails in the details, not the science.
We invest billions in developing breakthrough oncology therapies, then exclude real patients because of outdated templates and operational inertia.
A team celebrates a successful $30 million manufacturing validation campaign.
...